

Fabio A Zucca

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7769758/fabio-a-zucca-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

4,784
citations

32
h-index

50
g-index

50
ext. papers

5,936
ext. citations

7.4
avg, IF

5.29
L-index

#	Paper	IF	Citations
45	The role of iron in brain ageing and neurodegenerative disorders. <i>Lancet Neurology, The</i> , 2014 , 13, 1045-60.	60.1	811
44	The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 9843-8	11.5	342
43	Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. <i>Progress in Neurobiology</i> , 2017 , 155, 96-119	10.9	322
42	Protective and toxic roles of dopamine in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2014 , 129, 898-915	15	271
41	Melanins and melanogenesis: from pigment cells to human health and technological applications. <i>Pigment Cell and Melanoma Research</i> , 2015 , 28, 520-44	4.5	242
40	Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. <i>Trends in Neurosciences</i> , 2003 , 26, 578-80	13.3	202
39	MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. <i>Nature Communications</i> , 2014 , 5, 3633	17.4	185
38	Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. <i>Neurotoxicity Research</i> , 2011 , 19, 63-72	4.3	169
37	New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 17567-72	11.5	153
36	Neuromelanin of the human substantia nigra: an update. <i>Neurotoxicity Research</i> , 2014 , 25, 13-23	4.3	149
35	Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. <i>Journal of Neurochemistry</i> , 2008 , 106, 24-36	6	137
34	The structure of neuromelanin as studied by chemical degradative methods. <i>Journal of Neurochemistry</i> , 2003 , 86, 1015-23	6	134
33	Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. <i>Acta Neuropathologica</i> , 2008 , 116, 47-55	14.3	132
32	Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008 , 106, 1866-75	6	126
31	The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 14785-9	11.5	118
30	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. <i>Brain</i> , 2019 , 142, 2558-2571	11.2	109
29	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018 , 4, 11	9.7	100

28	Engineered nanoparticles. How brain friendly is this new guest?. <i>Progress in Neurobiology</i> , 2014 , 119-120, 20-38	10.9	96
27	The neuromelanin of human substantia nigra: physiological and pathogenic aspects. <i>Pigment Cell & Melanoma Research</i> , 2004 , 17, 610-7		95
26	Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases. <i>Angewandte Chemie - International Edition</i> , 2019 , 58, 6512-6527	16.4	87
25	A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. <i>Neurology</i> , 2006 , 67, S8-11	6.5	81
24	Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. <i>Journal of Neural Transmission</i> , 2006 , 113, 757-67	4.3	78
23	Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 5108-5115	11.5	64
22	Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease. <i>Npj Parkinsons Disease</i> , 2018 , 4, 17	9.7	61
21	Contrast mechanisms associated with neuromelanin-MRI. <i>Magnetic Resonance in Medicine</i> , 2017 , 78, 1790-1806	14.0	60
20	Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. <i>Trends in Neurosciences</i> , 2019 , 42, 384-401	13.3	49
19	Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. <i>PLoS ONE</i> , 2012 , 7, e48490	3.7	44
18	Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference. <i>Progress in Neurobiology</i> , 2006 , 78, 364-73	10.9	38
17	Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus. <i>Journal of Neurochemistry</i> , 2015 , 135, 768-76	6	37
16	Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry. <i>Journal of Neurochemistry</i> , 2016 , 138, 339-53	6	36
15	Biosynthetic pathway to neuromelanin and its aging process. <i>Pigment Cell and Melanoma Research</i> , 2012 , 25, 792-803	4.5	36
14	Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. <i>Journal of Neural Transmission</i> , 2004 , 111, 1253-65	4.3	36
13	The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. <i>Journal of Neural Transmission Supplementum</i> , 2003 , 145-55		32
12	Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. <i>Journal of Lipid Research</i> , 2007 , 48, 1457-62	6.3	24
11	Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2017 , 8, 501-512	5.7	23

10	A lysosome-plasma membrane-sphingolipid axis linking lysosomal storage to cell growth arrest. <i>FASEB Journal</i> , 2018 , 32, 5685-5702	0.9	23
9	The neurobiology of human aggressive behavior: Neuroimaging, genetic, and neurochemical aspects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 106, 110059	5.5	16
8	Reduction of the nitro group to amine by hydroiodic acid to synthesize o-aminophenol derivatives as putative degradative markers of neuromelanin. <i>Molecules</i> , 2014 , 19, 8039-50	4.8	14
7	Iron, copper and their proteins in substantia nigra of human brain during aging. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2005 , 263, 733-737	1.5	14
6	Neuromelanins in various regions of human brain are associated with native and oxidized isoprenoid lipids. <i>Archives of Biochemistry and Biophysics</i> , 2009 , 484, 94-9	4.1	12
5	Neuromelanins isolated from different regions of the human brain exhibit a common surface photoionization threshold. <i>Photochemistry and Photobiology</i> , 2009 , 85, 387-90	3.6	6
4	Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models. <i>Antioxidants</i> , 2021 , 10,	7.1	6
3	Dopamin, oxidativer Stress und Protein-Chinonmodifikationen bei Parkinson und anderen neurodegenerativen Erkrankungen. <i>Angewandte Chemie</i> , 2019 , 131, 6580-6596	3.6	5
2	Chapter 9:The Role of Iron in Neurodegeneration. <i>RSC Drug Discovery Series</i> , 2011 , 174-211	0.6	3
1	Overexpression of Vesicular Monoamine Transporter-2 may Block Neurotoxic Metabolites from Cytosolic Dopamine: a Potential Neuroprotective Therapy for Parkinson's Disease 2019 , 3, 143-148		2